Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James V. Caruso
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Beta
- 0.58
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -14.99
Financials
Net Income
$-7.97MEBITDA
$-8.10MFree Cash Flow
$-9.41MEPS (diluted)
$-0.46Shares Outstanding (diluted)
17.46M+16742.7%Operating Expenses
$8.10MCash & Debt
$24.58MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-21.79M | $-8.35 |
| 2024 | $0.00 | $-44.58M | $-36.52 |
| 2023 | $0.00 | $-42.77M | $-104.99 |
| 2022 | $0.00 | $-31.79M | $-135.18 |
| 2021 | $0.00 | $-24.12M | $-130.35 |
| 2020 | $0.00 | $-15.09M | $-228.55 |
| 2019 | $0.00 | $-14.09M | $-550.86 |
| 2018 | $0.00 | $-13.24M | $-1567.96 |
| 2017 | $0.00 | $-13.56M | $-3210.00 |
| 2016 | $0.00 | $-6.18M | $-6420.00 |
| 2015 | $0.00 | $-5.50M | $-21090.00 |
| 2014 | $0.00 | $-8.11M | $-53100.00 |
| 2013 | $0.00 | $-10.78M | $-114000.00 |
| 2012 | $0.00 | $-8.80M | $-138000.00 |
Valuation
CLRBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·12d ago·Neutral
Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates Presented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in Waldenström macroglobulinemia (WM)
View source ↗ - Newsglobenewswire.com·20d ago·Negative
…Financial Results and Host a Conference Call on Tuesday, November 10, 2026 FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company will report financial results for the third quarter ended September 30, 2026, and provide a corporate update on November 10, 2026, at 8:30 a.m.
View source ↗ - Newsglobenewswire.com·26d ago·Negative
…sine I 131 and its Potential Utility Across a Range of B-cell Malignancies FLORHAM PARK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today reported results from a case study highlighting a durable complete response in a heavily pretreated patient with diffuse large B-cell lymphoma (DLBCL) treated with iopofosine I 131.
View source ↗ - Newsglobenewswire.com·38d ago·Positive
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months
View source ↗ - Newsglobenewswire.com·54d ago·Positive
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy
View source ↗ - Newsseekingalpha.com·96d ago·Positive
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
View source ↗ - Newsseekingalpha.com·101d ago·Positive
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·101d ago·Negative
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program
View source ↗
Earnings
Wed, Mar 3(in 3 months)
Consensus estimate $-0.53 per share
Typical surprise +23.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.46 vs $-0.56beat
- Thu, Aug 13$-0.57 vs $-0.52miss
- Thu, May 14$-1.33 vs $-1.89beat
- Wed, Mar 4$-0.53 vs $-1.19beat
- Thu, Nov 13$-1.41 vs $-1.91beat
- Thu, Aug 14$-3.39 vs $-3.60beat
Estimates and results for CLRB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CLRB officers and directors.
- Bought
- $619k
- Sold
- $8.6m
17 trades
7 trades
- Longcor Jarrodbought
- Longcor Jarrodbought
- Caruso James Vbought
- Caruso James Vbought
- Neis Johnsold
- Caruso James Vbought
- Caruso James Vbought
- Longcor Jarrodbought
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CLRB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
